HOME › DRUGS › RETIFANLIMAB
ACTIVE SUBSTANCE / INN

RETIFANLIMAB

Brand name(s): Zynyz
EMA LISTED
APPLICATION WITHDRAWN
AUTHORISED
Carcinoma, Merkel Cell
Anus Neoplasms;Carcinoma, Squamous Cell
ACTIVE SUBSTANCE
Retifanlimab
REGULATORS
EMA
SPONSORS / MAH
Incyte Biosciences Distribution B.V.
TOTAL APPLICATIONS
2
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
ZynyzIncyte Biosciences Distribution B.V.Authorised19/04/2024Carcinoma, Merkel Cell
ZynyzIncyte Biosciences Distribution B.V.Application withdrawnAnus Neoplasms;Carcinoma, Squamous Cell

FULL INTELLIGENCE ON RETIFANLIMAB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →